GlassScriptPhysician profile
Sanet Torres-Torres
NPI 1770716466
$10,805.10
in general payments reported to CMS, 2019-2025
15 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Pediatric Infectious Diseases provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2021: $365 · 2022: $4,443 · 2023: $1,968 · 2024: $3,431 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,870 · Food and Beverage: $1,782 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,870.00 |
| Food and Beverage | $1,782.06 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $8,286.50 | 2022-2024 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Genzyme Corporation | $713.71 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.54 | 2022-2025 | Vpriv |
| Boston Scientific Corporation | $244.08 | 2021-2023 | |
| Valneva USA, INC. | $183.79 | 2023 | |
| Glaxosmithkline, LLC. | $156.28 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $138.23 | 2025 | |
| Shionogi INC | $124.99 | 2024 | Fetroja |
| Horizon Therapeutics Plc | $124.95 | 2023 | Actimmune |
| Alexion Pharmaceuticals, INC. | $117.34 | 2023 | |
| Allergan, INC. | $96.65 | 2019 | |
| Pfizer INC. | $78.76 | 2023 | |
| Pbg Puerto Rico LLC | $58.10 | 2022-2023 | |
| Sobi, INC | $40.18 | 2022 | |
| Biomarin Pharmaceutical INC. | $30.00 | 2023 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanet Torres-Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.